An analysis of patients treated with anti-PD-L1 therapies showed a notable beneficial effect of elevated BMI regardless of sex, with patients living with obesity showing greater overall survival (10). This evidence concerns the gene CD274 and obesity due to melanocortin 4 receptor deficiency.